Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07321873 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

A Phase 2 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
19
Study locations

NCT07321873 is a Phase 2 study of Arthritis, Psoriatic that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 240 participants, below the 561-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (57% lower). The trial reports 19 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07321873, a Phase 2 study of Arthritis, Psoriatic, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.

Conditions Studied

Arthritis, Psoriatic

Interventions

  • DRUG Placebo
  • DRUG JNJ-88545223

Study Locations (19)

Other

  • Peking University People's Hospital - Beijing
  • Ningbo medical center lihuili hospital - Ningbo
  • Hospital of the University of Occupational and Environmental Health - Kitakyushu-shi
  • Osaka Metropolitan University Hospital - Osaka
  • Sanuki Municipal Hospital - Sanuki

Florida

  • American Research, LLC - Cutler Bay
  • Innovation Medical Research Center - Palmetto Bay
  • Clinical Research of West Florida - Tampa
  • Conquest Research - Winter Park

California

  • Newport Huntington Medical Group - Huntington Beach
  • Rheumatology Center of San Diego - San Diego

Arkansas

  • Unity Health-White County Medical Center - Searcy

Georgia

  • Atlanta Research Center for Rheumatology - Marietta

Illinois

  • Willow Rheumatology and Wellness PLLC - Willowbrook

Indiana

  • Qualmedica Research - Evansville

North Carolina

  • Joint and Muscle Research Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2026-01-15
Est. Completion 2027-08-02
Phase Phase 2

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07321873

The ClinicalTrials.gov registry entry for NCT07321873 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 561-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (57% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07321873 reports 19 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, California.

Frequently Asked Questions

What is clinical trial NCT07321873 about?

NCT07321873 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joi...

What is the current status of trial NCT07321873?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-01-15. Estimated completion is 2027-08-02.

What conditions does trial NCT07321873 study?

This clinical trial studies the following conditions: Arthritis, Psoriatic.

What interventions are being tested in trial NCT07321873?

The interventions under investigation include: Placebo (DRUG), JNJ-88545223 (DRUG).

Who is sponsoring clinical trial NCT07321873?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07321873 being conducted?

This trial has 19 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Arthritis, Psoriatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Arthritis, Psoriatic

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.